IDM Pharma, Inc. (IDMI) Announces Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
IDM Pharma, Inc. announced that the European Commission has formally authorized MEPACT® (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor. MEPACT can now be marketed in the 27 Member States of the European Union, as well as in Iceland, Liechtenstein and Norway. "Today's approval of MEPACT is a significant milestone for physicians and patients in Europe, giving them access to the first new osteosarcoma treatment option in 20 years," commented Timothy P. Walbert, president and chief executive officer, IDM Pharma. "As our lead product candidate and first to receive approval,…